Cargando…

Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK)

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used to reduce hyperglycemia. The present study investigated the effects of a SGLT2 inhibitor, empagliflozin, on hyperglycemia in a novel rat model of non-obesity type 2 diabetes with enlarged kidney (DEK). METHODS: Male DEK ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Domon, Ayaka, Katayama, Kentaro, Sato, Touko, Tochigi, Yuki, Tazaki, Hiroyuki, Suzuki, Hiroetsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096081/ https://www.ncbi.nlm.nih.gov/pubmed/33945582 http://dx.doi.org/10.1371/journal.pone.0251135

Ejemplares similares

Characterization of Enlarged Kidneys and Their Potential for Inducing Diabetes in DEK Rats
por: Domon, Ayaka, et al.
Publicado: (2021)

Characterization of Novel Nonobese Type 2 Diabetes Rat Model with Enlarged Kidneys
por: Domon, Ayaka, et al.
Publicado: (2019)

Loss of Wwox Causes Defective Development of Cerebral Cortex with Hypomyelination in a Rat Model of Lethal Dwarfism with Epilepsy
por: Tochigi, Yuki, et al.
Publicado: (2019)

New insights into the role of empagliflozin on diabetic renal tubular lipid accumulation
por: Sun, Hong, et al.
Publicado: (2022)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function
por: Wang, Jinwu, et al.
Publicado: (2022)

Xanthophylls in Human Milk and Maternal Diet: A Cross-sectional Analysis of Data from the Japanese Human Milk Study Cohort
por: Ueno, Hiroshi M, et al.
Publicado: (2022)

No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro
por: Baer, Patrick C., et al.
Publicado: (2020)

Role of the DEK oncogene in the development of squamous cell carcinoma
por: Ishida, Kazuhisa, et al.
Publicado: (2020)

Rap1 Ameliorates Renal Tubular Injury in Diabetic Nephropathy
por: Xiao, Li, et al.
Publicado: (2014)

Hyperactivation of Nrf2 in early tubular development induces nephrogenic diabetes insipidus
por: Suzuki, Takafumi, et al.
Publicado: (2017)

Impact of empagliflozin on diabetic kidney disease
por: Koya, Daisuke
Publicado: (2017)

Empagliflozin Ameliorates Progression From Prediabetes to Diabetes and Improves Hepatic Lipid Metabolism: A Systematic Review
por: Hossain, Md Fahad, et al.
Publicado: (2022)

Changes in fatty acid composition in tissue and serum of obese cats fed a high fat diet
por: Fujiwara, Megumi, et al.
Publicado: (2015)

Empagliflozin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2020)

Empagliflozin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2022)

Empagliflozin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Empagliflozin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Urinary angiotensinogen is a marker for tubular injuries in patients with type 2 diabetes
por: Terami, Takahiro, et al.
Publicado: (2013)

Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease
por: Sawada, Takahiro, et al.
Publicado: (2020)

The SAF-box domain of chromatin protein DEK
por: Böhm, Friederike, et al.
Publicado: (2005)

Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Albugami, Muneerah M., et al.
Publicado: (2020)

A DEK domain-containing protein GhDEK2D mediated Gossypium hirsutum enhanced resistance to Verticillium dahliae
por: Zhou, Jinglong, et al.
Publicado: (2022)

Empagliflozin Administration Can Decrease the Dose of Loop Diuretics and Prevent the Exacerbation of Renal Tubular Injury in Patients With Compensated Heart Failure Complicated by Diabetes
por: Shirakabe, Akihiro, et al.
Publicado: (2020)

Proximal Tubular Hypertrophy and Enlarged Glomerular and Proximal Tubular Urinary Space in Obese Subjects with Proteinuria
por: Tobar, Ana, et al.
Publicado: (2013)

Optical Coherence Tomography Angiography Biomarkers in Thai Patients With Diabetic Nephropathy: A Diabetic Eye and Kidney Diseases (DEK-D) Study
por: Surawatsatien, Nuntachai, et al.
Publicado: (2023)

Empagliflozin in the treatment of type 2 diabetes: evidence to date
por: Shubrook, Jay H, et al.
Publicado: (2015)

Myopathy secondary to empagliflozin therapy in type 2 diabetes
por: Gao, Frank, et al.
Publicado: (2020)

Empagliflozin: Euglycemic and hyperglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Empagliflozin: Euglycaemic diabetic ketoacidosis: 2 case reports
Publicado: (2021)

Empagliflozin/linagliptin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Effect of Empagliflozin on Sphingolipid Catabolism in Diabetic and Hypertensive Rats
por: Pérez-Villavicencio, Roxana, et al.
Publicado: (2022)

Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice
por: Huang, Chiang-Chi, et al.
Publicado: (2021)

Empagliflozin Ameliorates Type 2 Diabetes-Induced Ultrastructural Remodeling of the Neurovascular Unit and Neuroglia in the Female db/db Mouse
por: Hayden, Melvin R., et al.
Publicado: (2019)

The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes
por: Iannantuoni, Francesca, et al.
Publicado: (2019)

Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis
por: Ray, Gretchen M., et al.
Publicado: (2019)

Effect of Empagliflozin in Preventing Progression of Renal Dysfunction in Diabetic Patients With Compensated Heart Failure
por: Imamura, Teruhiko
Publicado: (2021)

Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats
por: Kuno, Atsushi, et al.
Publicado: (2020)

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
por: Lin, Bowen, et al.
Publicado: (2014)

Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study
por: Lee, Paul Chi Ho, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5ot08a8qg9qoff3i8eb8viuc8i